Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma

BACKGROUND: The survival advantage of induction chemotherapy (IC) followed by locoregional treatment is controversial in locally advanced head and neck squamous cell carcinoma (LAHNSCC). We previously showed feasibility and safety of cetuximab-based IC (paclitaxel/carboplatin/cetuximab—PCC, and doce...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Haddad, R.I., Massarelli, E., Lee, J.J., Lin, H.Y., Hutcheson, K., Lewis, J., Garden, A.S., Blumenschein, G.R., William, W.N., Pharaon, R.R., Tishler, R.B., Glisson, B.S., Pickering, C., Gold, K.A., Johnson, F.M., Rabinowits, G., Ginsberg, L.E., Williams, M.D., Myers, J., Kies, M.S., Papadimitrakopoulou, V.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Head and neck tumor
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360148/
https://ncbi.nlm.nih.gov/pubmed/30596812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy549
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items